Evidence map›Paper›PMID 30250996›Full record

ArticleMolecular biology reports2018

Expression patterns and bioinformatic analysis of miR-1260a and miR-1274a in Prostate Cancer Tunisian patients.

Rahma Said, Yoelsis Garcia-Mayea, Nesrine Trabelsi, Nouha Setti Boubaker, Cristina Mir, Ahlem Blel, Nidhal Ati, Rosanna Paciucci, Javier Hernández-Losa, Soumaya Rammeh and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Cell journal · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Rahma SaidLaboratory of Protein Engineering and Bio-active Molecules, National Institute of Applied Science and Technology - University of Carthage, Tunis, Tunisia.
Yoelsis Garcia-MayeaBiomedical Research in Cancer Stem Cells Group, Pathology Department, Vall d'Hebron Research Institute (VHIR), Passeig Vall d´Hebron 119-129, 08035, Barcelona, Spain.ORCID http://orcid.org/0000-0002-9395-7471
Nesrine TrabelsiLaboratory of Protein Engineering and Bio-active Molecules, National Institute of Applied Science and Technology - University of Carthage, Tunis, Tunisia.ORCID http://orcid.org/0000-0003-1450-4659
Nouha Setti BoubakerLaboratory of Protein Engineering and Bio-active Molecules, National Institute of Applied Science and Technology - University of Carthage, Tunis, Tunisia.
Cristina MirBiomedical Research in Cancer Stem Cells Group, Pathology Department, Vall d'Hebron Research Institute (VHIR), Passeig Vall d´Hebron 119-129, 08035, Barcelona, Spain.ORCID http://orcid.org/0000-0003-3137-6521
Ahlem BlelPathology Anatomy and Cytology Department, Charles Nicolle Hospital, Tunis, Tunisia.ORCID http://orcid.org/0000-0001-6702-3889
Nidhal AtiUrology Department, Charles Nicolle Hospital, Tunis, Tunisia.
Rosanna PaciucciBiomedical Research Group of Urology, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0002-1087-6378
Javier Hernández-LosaBiomedical Research in Cancer Stem Cells Group, Pathology Department, Vall d'Hebron Research Institute (VHIR), Passeig Vall d´Hebron 119-129, 08035, Barcelona, Spain.ORCID http://orcid.org/0000-0003-1526-3201
Soumaya RammehPathology Anatomy and Cytology Department, Charles Nicolle Hospital, Tunis, Tunisia.ORCID http://orcid.org/0000-0003-0366-4630
Amine DerouicheUrology Department, Charles Nicolle Hospital, Tunis, Tunisia.
Mohamed ChebilUrology Department, Charles Nicolle Hospital, Tunis, Tunisia.ORCID http://orcid.org/0000-0001-8387-7593
Matilde E LLeonartBiomedical Research in Cancer Stem Cells Group, Pathology Department, Vall d'Hebron Research Institute (VHIR), Passeig Vall d´Hebron 119-129, 08035, Barcelona, Spain.ORCID http://orcid.org/0000-0002-6196-7405
Slah OuerhaniLaboratory of Protein Engineering and Bio-active Molecules, National Institute of Applied Science and Technology - University of Carthage, Tunis, Tunisia. slah_mekni@yahoo.fr.ORCID http://orcid.org/0000-0002-3651-4690
Hôpital Charles-Nicolle · TNUniversity of Carthage · TNVall d'Hebron Institut de Recerca · ESUniversitat Autònoma de Barcelona · ES

Funding

Instituto de Salud Carlos III PI12/01104Instituto de Salud Carlos III PI15/01262
6 · The paper itself

Abstract

Currently, microRNAs (miRs) represent great biomarkers in cancer due to their stability and their potential role in diagnosis, prognosis and therapy. This study aims to evaluate the expression levels of miRs-1260 and -1274a in prostate cancer (PC) samples and to identify their eventual targets by using bioinformatic analysis. In this project, we evaluated the expression status of miRs-1260 and -1274a in 86 PC patients and 19 controls by using real-time quantitative PCR and 2

Indexed as

AgedAged, 80 and overBiomarkers, TumorCase-Control StudiesCell Line, TumorComputational BiologyGene Expression Regulation, NeoplasticHumansLymphatic MetastasisMaleMicroRNAsNeoplasm Recurrence, LocalPrognosisProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesBiomarkers, TumorMicroRNAsMIRN1260 microRNA, humanMIRN1274 microRNA, humanProstate-Specific AntigenEpigeneticMiR-1260MiR-1274aOver-expressionProstate cancerTunisia

Identifiers

PMID30250996
OpenAlexW2893323712

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.